Basic Info

150 Munson Street 25 Science Park 2nd Fl
New Haven, CT 06511
(203) 772-2888
Preferred contact:
  N/A - President/CEO
Helix Therapeutics LLC
Business Identifier: deoxyribonucleic acid (DNA) based therapeutics
Public Profile:
Spun out of Yale University, Helix Therapeutics, Inc. develops deoxyribonucleic acid (DNA) based therapeutics. It develops novel sequence-specific gene-targeting reagents for the treatment of HIV/AIDS and common genetic diseases, such as sickle cell anemia, thalassemia, and cystic fibrosis.The mission of Helix is to establish cures for select genetic diseases using triplex-forming oligonucleotide (TFO) technology. Specific targeting of genetic information in human hematopoietic stem cells leads to stable, heritable correction of responsible mutations.

 Synopsis: Awardee Business Condition
Year Founded 2006 IP Holdings N/A
Employee Range 10-14 VC funded? Yes
Revenue Range .5M-1M Private/Public Privately Held
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
2010 1 NIH $228,490 Beta-Globin Gene Correction Using Peptide Nucleic Acids For The Treatment Of Sick
2008 1 NIH $99,999 Targeted Ccr5 Gene Inactivation Using Peptide Nucleic Acids


Media coverage